Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Fineline Cube Apr 12, 2026
Company Deals

Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline

Fineline Cube Apr 12, 2026
Company Deals

NorrDia Medical Raises RMB 100M+ to Complete Bellco Acquisition – Builds Global Blood Purification Platform

Fineline Cube Apr 12, 2026
Company Deals

Vivatides Therapeutics Closes $54M Series A to Advance Extrahepatic Oligonucleotide Delivery Platform – Led by Qiming Venture Partners

Fineline Cube Apr 12, 2026
Company Deals

C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology

Fineline Cube Apr 10, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Fineline Cube Apr 12, 2026
Company Drug

Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC

Fineline Cube Apr 12, 2026
Company Deals

Grand Pharma Acquires Stake in Xeltis and Licenses aXess for Hemodialysis in Greater China

Fineline Cube Jul 19, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced the acquisition of an 11% stake in...

Company Deals

Fermion Secures Series B Financing to Advance AI-Driven Drug Development

Fineline Cube Jul 18, 2022

Guangzhou-based AI biotech Fermion has raised over RMB100 million ($14.8 million) in a Series B...

Company Deals

Biotree Raises $14.8M in Series A Financing to Expand Multi-Omics Platform

Fineline Cube Jul 18, 2022

Shanghai-based multi-omics specialist Biotree has raised nearly RMB100 million ($14.8 million) in a Series A...

Company Drug

Kexing Pharmaceutical’s SHEN26 COVID-19 Drug Receives NMPA Approval for Clinical Trials

Fineline Cube Jul 18, 2022

China-based Kexing Pharmaceutical (SHA: 688136) announced that its oral small-molecule COVID-19 drug SHEN26, co-developed with...

Company Deals Digital

WeDoctor Partners with Jinan Innovation Zone to Launch Dual Healthcare Platform

Fineline Cube Jul 18, 2022

China-based WeDoctor Holdings Ltd, a Tencent-backed online medical service platform, has partnered with Jinan Innovation...

Company Drug

ImmuneOnco’s IMM2902 Receives FDA Fast-Track Designation for CD47/HER2 Targeting

Fineline Cube Jul 18, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced that the U.S. Food and Drug Administration (FDA) has...

Policy / Regulatory

VBP Round 7 Drug Procurement Contract Awards Top Winners Revealed

Fineline Cube Jul 18, 2022

China’s 7th national Volume-Based Procurement (VBP) round concluded with winning bids for 60 drug products...

Company

Merck KGaA Launches Uptune Program in Asia, Offers Startups Up to €100,000

Fineline Cube Jul 18, 2022

Germany-based life sciences giant Merck KGaA has launched the Uptune program in Asia, offering up...

Company Drug

Pfizer Launches Cejemly in China for Stage III NSCLC, Expands Immunotherapy Reach

Fineline Cube Jul 18, 2022

Pfizer announced the commercial launch of Cejemly (sugemalimab) in China for Stage III non-small cell...

Company Deals

Sihuan Pharma to Sell Generic Drug Businesses, Shift Focus to Aesthetics and Biologics

Fineline Cube Jul 18, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced plans to divest a portion of...

Company Drug

Luye Pharma’s Lurbinectedin Receives Hainan Approval for SCLC Treatment

Fineline Cube Jul 18, 2022

China-based Luye Pharma Group (HKG: 2186) announced approval from the Hainan Medical Products Administration for...

Company Drug

Novartis’ Aimovig Launches in China via GBA Early Access Scheme for Migraine Treatment

Fineline Cube Jul 15, 2022

Swiss pharma giant Novartis’ (NYSE: NVS) migraine therapy Aimovig (erenumab) was administered for the first...

Drug

CStone Pharmaceuticals’ Gavreto Wins Hong Kong Approval for RET Fusion NSCLC

Fineline Cube Jul 15, 2022

CStone Pharmaceuticals (HKG: 2616) announced that its RET inhibitor Gavreto (pralsetinib) has received marketing approval...

Company Medical Device

NMPA Approves RocketHeart’s LV Assist System and Our United Group’s Radiation Therapy Device

Fineline Cube Jul 15, 2022

The National Medical Products Administration (NMPA) has approved marketing for two innovative medical devices: RocketHeart’s...

Company Deals Digital

Ping An Good Doctor Partners with China Biotech Services for Cancer Testing and BNCT Treatment

Fineline Cube Jul 15, 2022

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...

Company Drug

Kelun Pharma’s SKB264 ADC Receives NMPA Green Light for Phase II Solid Tumor Study

Fineline Cube Jul 15, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that its antibody drug conjugate (ADC)...

Company Drug

Luye Pharma Initiates Phase III Study of Trulicity Biosimilar BA5101 in China

Fineline Cube Jul 15, 2022

China-based Luye Pharma Group (HKG: 2186) announced the initiation of a Phase III clinical study...

Company Deals

Shanghai Electric and Siemens Partner on Localization of High-End Medical Equipment

Fineline Cube Jul 15, 2022

China’s Shanghai Electric Group has partnered with Germany-based Siemens Healthineers to localize high-end medical equipment,...

Company Drug

Beijing Science Sun’s LZ901 Shingles Vaccine Receives FDA IND Approval

Fineline Cube Jul 15, 2022

China-based Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced that its subsidiary Beijing Luzhu...

Company Deals

Ningbo HicRen Biotech Completes RMB100M Pre-Series C Financing for Orthopedic Robots

Fineline Cube Jul 15, 2022

Ningbo HicRen Biotechnology Co., Ltd, a China-based robotics-driven minimally invasive orthopedics platform, announced the completion...

Posts pagination

1 … 631 632 633 … 648

Recent updates

  • Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline
  • Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies
  • Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies
  • Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC
  • Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline

Company Drug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Company Drug

Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.